Abstract
Recently, molecular targeting agents occupy a prominent position in the anti-cancer drug market. Many of the tyrosine kinase inhibitors have been approved for treatment of several tumor types ranging from infrequently occurring tumors to the more common lung and colon cancers. Recently, multi-tyrosine kinase inhibitors such as sorafenib and sunitunib have shown to be active against renal cell and hapatocellular carcinoma. Thus, multi-target tyrosine kinase inhibitors are highlighted. Biomarkers can adequately select a sub-population of patients designated for the specific molecular targeting agents. A clinical study of the patient sub-population can improve the efficiency of the clinical development of the anti-cancer agents. A pharmacodynamic study that monitors the targets or the surrogate markers during treatments is important and leads to the POC of the drugs. We hope to discuss following points; 1) Should a sub-population be selected by clinical factor or biomarkers? 2) How to select a standard assay system? 3) How to access the clinical samples? 4) Can circulating samples improve feasibility?
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22: 1382–1388
McShane LM, Altaian DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23: 9067–9072
Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983–991
Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33: 49–54
Simon R (2005) Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23: 7332–7341
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418–8423
van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999–2009
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer
About this paper
Cite this paper
Nishio, K., Arao, T. (2009). Biomarker Research for Development of Molecular Target Agents. In: Tachikawa, T., Nose, K., Ohmori, T., Adachi, M. (eds) New Trends in the Molecular and Biological Basis for Clinical Oncology. Springer, Tokyo. https://doi.org/10.1007/978-4-431-88663-1_2
Download citation
DOI: https://doi.org/10.1007/978-4-431-88663-1_2
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-88662-4
Online ISBN: 978-4-431-88663-1
eBook Packages: MedicineMedicine (R0)